This record was last updated May 7, 2026 (before its estimated June 2026 completion). Its status may not reflect the trial's current state.
Summary
The Goal of this this clinical trial is to assess and compare the eradication rate of triple and quadruple therapy during treating helicobacter pylori infection among patients presented with dyspepsia. It will also assess the patient reported adverse events among two groups.
H pylori infection will be confirmed by CLO (RUT) test and stool antigen test both.
Standard triple therapy will be based on Esomeprazole 20 mg BD, Clarithromycin 500mg BD and Amoxicillin 1gm BD. Bismuth Quadruple therapy consists of Bismuth subcitrate 120mg QDS, Tetracycline 500mg QDS and Metronidazole 500mg TDS. Patient will be confirmed H pylori eradication 4 weeks after completion of treatment by Stool antigen test only.
Protocol Amendment History
2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-30; most recent amendment 2026-05-04.
Status change: Not Yet Recruiting → Enrolling by Invitation2026-01-24